Atlas Trials

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Clinical trial NCT03358472 · COMPLETED

Trial details

NCT number
NCT03358472
Sponsor
Incyte Corporation
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Head and Neck Cancer
Start date
2017-12-01
Primary completion
2018-07-19
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.